1:14 PM
 | 
Jun 15, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Eisai, Purdue's insomnia candidate does not impair driving in Phase I

Eisai Co. Ltd. (Tokyo:4523) and Purdue Pharma L.P. (Stamford, Conn.) reported top-line data from the Phase I Study 106 showing that insomnia candidate lemborexant (E2006) given each night at bedtime met the primary endpoint of not impairing driving performance vs. placebo. Driving performance impairment was measured by mean changes in standard deviation of lateral...

Read the full 246 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >